Alternatives to Andrew Meds

A menopause-focused program that bills insurance for eligible visits. The visit is covered in network or $250 self-pay, and the medication is billed separately from $164 per four-week supply — both figures published. It's built for perimenopause, not the postpartum year.

• $21.33 less per month on average than Andrew Meds
• offers FDA-approved brand pens, not just compounded
• scores 72/100 against Andrew Meds's 44

The widest menu on our list — injections, sublingual lozenges, daily drops, four brand-name pens and the approved oral GLP-1 — with three compounding pharmacies named, prices published for every plan length, and cancellation terms among the most restrictive we have read.

• offers FDA-approved brand pens, not just compounded
• scores 76/100 against Andrew Meds's 44

Price-first and nationwide: flat, all-inclusive compounded pricing at $175 and $235 month to month, down to $99 and $125 on a 12-month plan — strong if you read the prepay fine print.

• $24 less per month on average than Andrew Meds
• scores 80/100 against Andrew Meds's 44

Physician-founded and genuinely cheap, with both molecules in a lozenge or a shot and a free MD visit — but a February 2026 FDA misbranding letter is a caveat a mother should read before signing up.

• $70 less per month on average than Andrew Meds
• scores 80/100 against Andrew Meds's 44

This is a real surgical practice rather than a telehealth brand — a Hollywood, Florida bariatric center with a named surgeon, doing gastric sleeves and bypasses alongside the injections. Semaglutide runs $69 a week or $179 a month; tirzepatide starts at $279. Two things need care. Its package labels overstate their own length — "2.5-Month (10 Weeks)" is 2.3 months and "5-Month (20 Weeks)" is 4.6 — and the practice markets retatrutide, a drug that is not approved anywhere for anything.

• $20 less per month on average than Andrew Meds
• offers FDA-approved brand pens, not just compounded
• scores 50/100 against Andrew Meds's 44

Semaglutide: Current semaglutide cash price not publicly itemized; tirzepatide: Compounded from $189/mo. Zepbound is advertised from $445 monthly, but the current public catalog does not establish a semaglutide cash price.

• $10 less per month on average than Andrew Meds
• offers FDA-approved brand pens, not just compounded
• scores 50/100 against Andrew Meds's 44

FDA warning letter #728279 (June 2026), which names Eden's website — read that first. Then read the price twice: the advertised $99 is medication alone, with a required $99-a-month membership on top.

• $1 less per month on average than Andrew Meds
• offers FDA-approved brand pens, not just compounded
• scores 47/100 against Andrew Meds's 44

Semaglutide: $199/mo; tirzepatide: Starting at $399/mo. Oral semaglutide starts at $299 and oral tirzepatide at $399; confirm your dose, plan length and cancellation terms.

• scores 78/100 against Andrew Meds's 44

Four named pharmacies, a named prescribing partner and brand-name Wegovy, Zepbound and Ozempic alongside the compounded line — that is a fuller disclosure than most providers we review manage. Compounded GLP-1 injections start at $179 a month and daily dissolvable tablets at $249, and the price attaches to the form rather than the molecule: the product page never says whether you are getting semaglutide or tirzepatide, and the terms confirm both are in scope. Two things deserve a mother's attention before she enrolls. The brand products are priced as a membership plus an undisclosed medication cost, and that membership is quoted at two different figures on one page, $99 beside Zepbound and Wegovy and $171 beside Ozempic. And the terms state that if a provider decides a different molecule suits you better, staying enrolled is itself your consent to the switch and the charges continue. It also discloses, unusually plainly, that people shown in its advertising may be actors or artificial intelligence rather than clinicians.

• $20 less per month on average than Andrew Meds
• offers FDA-approved brand pens, not just compounded